uploads/2015/12/Graph-Part-4-Dec-17-20151.png

Waters Led XLV’s Electronic Subgroup

By

Updated

XLV’s subgroup

The Health Care Select Sector SPDR ETF (XLV) provides exposure to different sub-industries of biotech industries. On December 16, 2015, the biotechnology subgroup returned 1.5%, the electronics subgroup returned 1.9%, the healthcare products subgroup gained 1.5%, the healthcare services went up by 0.3%, the pharmaceuticals subgroup gained 1.1%, and the software subgroup gained 1.2%.

XLV’s electronics subgroup outperformed the SPDR S&P 500 ETF (SPY) and XLV, which gave returns of 1.5% and 1.3%, respectively. The electronics subgroup has a weight of ~3.1% in XLV’s portfolio. The pharmaceuticals subgroup has the highest exposure of ~50.3% of XLV’s portfolio. The electronics subgroup includes stocks like PerkinElmer (PKI) and Thermo Fisher Scientific (TMO), which gave returns of 2.4% and 2.2%, respectively.

 

The above graph reflects the performances of XLV’s subgroup on a day-to-day basis. For the month of December to date, the biotechnology subgroup and pharmaceutical subgroup have outperformed with a return of 2.6% and 2.4%, respectively.

Article continues below advertisement

Waters rose by 1.6%

Waters (WAT) went up by 1.6% on December 16, 2015. As per the press release, WAT announced “a new 24-sample option for its highly acclaimed GlycoWorks RapiFluor-MS N-Glycan Kit. The new format processes 24 samples – eight at a time – and opens the door further to laboratories that want to begin realizing the benefits that RapiFluor-MS brings to glycan analysis.”

WAT closed at $133.73 and was trading above its 100-day moving average price of $126.45, and it was also trading above its 20-day moving average price of $131.44. Year-to-date, WAT has given a return of 18.6%. WAT has a trailing-12-month price-to-earnings multiple of 23.8x. WAT’s book value stood at $24.11. With its current price, the stock is trading at a price-to-book value of 5.55x. WAT has a weight of 0.4% in XLV’s portfolio.

Advertisement

More From Market Realist